N. Meningitidis Carriage Study
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Procedure: Posterior pharyngeal swabOther: Data collection
- Registration Number
- NCT01808365
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This carriage study aims to evaluate the presence of meningococcus in Asian populations (and potential for disease) and explore the extent and serogroup distribution of meningococci circulating in the population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Subjects who the investigator believes can and will comply with the requirements of the protocol or subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject/from the parent(s)/LAR of the subject.
- Asymptomatic subjects attending a school or university.
- A male or female between, and including 5 and 24 years of age at the time of enrollment.
Exclusion Criteria
- Subjects who have received a meningococcal conjugate vaccine.
- Use of any investigational or non-registered product within one week before the enrollment visit.
- Acute respiratory tract infection within 14 days of sample collection.
- Immune deficiencies, haematological disorders and oncological disease.
- Use of steroids or immunosuppressant drugs within 14 days of sample collection.
- Administration of antibiotics within the 2 weeks preceding the collection of sample.
- Cranio-facial malformations prohibiting the collection of posterior pharyngeal swabs.
- Child in care.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Study cohort Posterior pharyngeal swab - Study cohort Data collection -
- Primary Outcome Measures
Name Time Method Assessing the carriage prevalence of N.meningitidis using posterior pharyngeal swabs At enrollment (Day 0)
- Secondary Outcome Measures
Name Time Method Further characterization of any carried N. meningitidis using Multi Locus Sequence Typing At enrollment (Day 0) The serogroup (determined by Polymerase Chain Reaction) of any isolated N. Meningitidis colonies At enrollment (Day 0)
Trial Locations
- Locations (1)
GSK Investigational Site
🇵🇭Manila, Philippines